Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.72 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13304869 | 0.90 | GSK3B (0.77) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13305295 | 0.89 | GSK3B (0.81) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL12953000 | 0.89 | GSK3B (1.00) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13146410 | 0.89 | GSK3B (0.79) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13146324 | 0.88 | GSK3B (0.77) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL14581374 | 0.84 | GSK3B (0.69) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13305396 | 0.84 | GSK3B (0.57) | GSK3BCHEK1CDK2CCNA2CCNA1 | |
| SCHEMBL13146320 | 0.83 | GSK3B (0.68) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13304987 | 0.83 | GSK3B (0.59) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13304614 | 0.83 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885CHEK1 60/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.